West of Scotland Clinical Genetics Service, Southern General Hospital, Glasgow, United Kingdom.
Department of Obstetrics and Gynaecology, Victoria Hospital, Kirkcaldy, United Kingdom.
Fertil Steril. 2015 Apr;103(4):1021-1030.e1. doi: 10.1016/j.fertnstert.2015.01.008. Epub 2015 Feb 20.
To clinically and genetically investigate women with müllerian disorders, including Mayer-Rokitanksy-Kuster-Hauser (MRKH) syndrome.
Two-year prospective clinical and laboratory study.
Not applicable.
PATIENT(S): Thirty-five women over 16 years of age with a müllerian disorder, including MRKH.
INTERVENTION(S): Women were recruited from specialist gynecology clinics or identified from the Scottish Disorders of Sex Development Register (www.sdsd.scot.nhs.uk/index.html). Associated abnormalities were detected by clinical examination, imaging studies, and biochemical analyses. Chromosomal microduplications and microdeletions were detected by array comparative genomic hybridization (CGH) and validated by fluorescence in situ hydridization.
MAIN OUTCOME MEASURE(S): Identification of associated congenital and biochemical abnormalities and identification of regions of genomic imbalance using array CGH.
RESULT(S): Associated congenital anomalies were common, present in 25/35 (71%) of affected women, particularly renal and skeletal abnormalities, which were present in 15/35 (43%) and 17/35 (49%) women, respectively. Using array CGH, novel or recurrent regions of genomic imbalance were identified in 4/11 (36%) women with MRKH and in 5/24 (21%) women with other müllerian abnormalities.
CONCLUSION(S): Additional congenital abnormalities and regions of genomic imbalance are common in women with müllerian disorders, including MRKH. Recurrent microdeletions and microduplications associated with MRKH implicate specific possibly causative genes. The investigation of women with müllerian disorders should be thorough, and array CGH should be considered, given the potential highly significant familial implications of a chromosomal abnormality.
对存在 Müllerian 发育障碍的女性(包括 Mayer-Rokitanksy-Kuster-Hauser 综合征[MRKH])进行临床和基因研究。
为期两年的前瞻性临床和实验室研究。
不适用。
35 名年龄在 16 岁以上的存在 Müllerian 发育障碍的女性,包括 MRKH 患者。
从专科妇科诊所招募女性,或从苏格兰性发育障碍登记处(www.sdsd.scot.nhs.uk/index.html)识别。通过临床检查、影像学研究和生化分析检测相关异常。通过阵列比较基因组杂交(CGH)检测染色体微重复和微缺失,并通过荧光原位杂交进行验证。
鉴定相关先天性和生化异常,并使用阵列 CGH 鉴定基因组失衡区域。
常见的先天性异常,35 名受影响女性中有 25 名(71%)存在,尤其是肾和骨骼异常,分别有 15 名(43%)和 17 名(49%)女性存在。使用阵列 CGH,在 11 名(36%)MRKH 患者和 24 名(21%)其他 Müllerian 发育异常患者中发现了新的或反复出现的基因组失衡区域。
在存在 Müllerian 发育障碍的女性中,包括 MRKH,常伴有其他先天性异常和基因组失衡区域。与 MRKH 相关的反复微缺失和微重复提示特定的可能致病基因。鉴于染色体异常可能具有重要的家族意义,对 Müllerian 发育障碍女性的调查应全面,并考虑使用阵列 CGH。